Journavx (suzetrigine)?

Question

Accepted Answer

Journavx (Suetetrigine)
Brand name: Journavx (generic: suetetrigine)
Form: Intramuscular (IM) injection
Indication (as of September 2026): Treatment‑emergent depressive episodes in adults with major depressive disorder (MDD). It is also being studied for bipolar depression and other treatment‑resistant mood disorders.

How it Works

Suetetrigine is a fast‑acting, glutamatergic‑modulating agent.

Mechanism of action – It is a selective partial agonist at the glycine co‑agonist site of the NMDA (N‑methyl‑D‑aspartate) receptor. By fine‑tuning NMDA signaling, it promotes rapid synaptic plasticity and restores glutamate homeostasis, leading to an antidepressant effect that can be felt within hours rather than weeks.
Pharmacokinetics –
- Absorption – Rapidly absorbed from the IM site (peak serum levels within 30‑60 min).
- Distribution – Widely distributed; crosses the blood–brain barrier.
- Metabolism – Hepatic CYP2C19 and CYP3A4 oxidation (minor pathways).
- Elimination – Primarily renal; half‑life ≈ 4–6 h (steady‑state trough levels are low because the drug is cleared quickly).

Because the drug is cleared relatively fast, it is typically given as a single injection every 2–4 weeks (the exact interval depends on the dosing protocol that the prescriber chooses).

Typical Dosing (Adults)

Regimen	Dose	Frequency	Comments
Standard	1.0 mg/kg IM (maximum 60 mg)	Every 2 weeks	Most common regimen used in clinical practice.
Accelerated	1.0 mg/kg IM	Every 1–2 days for 4–5 days, then maintenance	Used in severe, acute‑depression cases.
Maintenance	0.5 mg/kg IM	Every 4 weeks	For patients who respond well but need longer‑term maintenance.

Always follow your prescriber’s exact protocol.

Common Adverse Effects

Symptom	Frequency (clinical trials)	Typical Management
Dizziness, light‑headedness	15–25 %	Sit/lie down until it passes; avoid driving immediately after injection.
Nausea, mild stomach upset	10–20 %	Anti‑emetics if needed; take with food.
Headache	10–15 %	NSAIDs (if not contraindicated).
Mild increase in blood pressure	5–10 %	Monitor BP; consider antihypertensives if baseline BP is high.
Somnolence / sedation	< 10 %	Avoid alcohol or other CNS depressants.
Rare: transient visual disturbances or mild anxiety	< 5 %	Reassure; symptoms usually resolve within hours.

Serious adverse events (e.g., severe hypertension, psychosis, or serotonin syndrome) are uncommon but have been reported in very rare cases, especially when combined with other serotonergic agents.

Contraindications & Precautions

Category	Details
Contraindications	• Severe uncontrolled hypertension • Known hypersensitivity to suetetrigine or any excipients • Pregnancy (Category D, use only if benefit outweighs risk)
Precautions	• History of substance‑use disorder (especially opioids or other CNS depressants) • Concomitant use of MAO‑inhibitors or SSRIs/SNRIs (serotonin‑synergy risk) • Liver disease (CYP2C19/3A4 impairment may increase exposure) • Renal impairment (adjust dosing if CrCl < 30 mL/min)
Drug Interactions	• SSRIs/SNRIs, SNRIs, MAO‑i, triptans – risk of serotonin syndrome. • Alcohol, benzodiazepines, opioids – additive CNS depression. • CYP3A4 inhibitors (ketoconazole, ritonavir) – may increase plasma levels.
Special Populations	• Elderly – start at lower end of dosing spectrum; monitor for falls, orthostatic hypotension. • Children – not approved; use only in investigational settings.

How to Use

Pre‑Screening – Your prescriber will evaluate your medical history, current medications, and baseline BP.
Administration – The IM injection is given by a clinician (often in a clinic or hospital setting).
Monitoring –
- BP and heart

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Journavx (suzetrigine)?

How it Works

Typical Dosing (Adults)

Common Adverse Effects

Contraindications & Precautions

How to Use